Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-08-23
2005-08-23
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S04400A, C536S022100, C536S023100, C536S023500, C435S069100, C435S069600
Reexamination Certificate
active
06933284
ABSTRACT:
The present invention relates to the study and control of atherosclerosis through the modulation of LDL-proteoglycan binding at Site B (amino acids 3359-3369) of the apo-B100 protein in LDL. The invention encompasses methods of identifying compounds which modulate LDL-proteoglycan binding, methods of identifying compounds which modulate atherosclerotic lesion formation, and methods of modulating the formation of atherosclerotic lesions. The invention also encompasses mutant apo-B100 proteins and LDL which exhibit reduced proteoglycan binding while maintaining LDL-receptor binding, polynucleotides which encode these apo-B100 proteins, as well as cells and animals which express the mutant apo-B100 proteins.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5350671 (1994-09-01), Houghton et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5656465 (1997-08-01), Panicali et al.
patent: 5672344 (1997-09-01), Kelley et al.
patent: 5851529 (1998-12-01), Guber et al.
patent: 0 200 362 (1986-12-01), None
patent: 0 201 184 (1986-12-01), None
patent: 0 229 701 (1987-07-01), None
patent: WO 84/03506 (1984-09-01), None
patent: WO 84/03564 (1984-09-01), None
patent: WO 95/04064 (1995-02-01), None
Law et al. “A cross-species comparison of the Apolipoprotein B domain that binds to the LDL receptor.” J. of Lipid Research. vol. 31, pp. 1109-1120. 1990.
Antibodies: A Laboratory Manual.(1988) Harlow, E. and D. Lane, Eds. (Table of Contents).
Arnold, K. et al., (1992). “Lipoprotein-Receptor Interactions” inLipoprotein Analysis. A Practical Approach.Converse, C. A. and E. R. Skinner, Eds. Oxford University Press: Oxford, pp. 145-168.
Basu, S. et al. (1976) “Degradation of Cationized Low Density Lipoprotein and Regulation of Cholesterol Metabolism in Homozygous Familial Hypercholesterolemia Fibroblasts”Proc. Natl. Acad. Sci.USA 73:3178-3182.
Borén, J. et al. (1996). “A Simple and Efficient Method for Making Site-Directed Mutants, Deletions, and Fusions of Large DNA Such as P1 and BAC Clones,”Genome Res.6:1123-1130.
Borén, J. et al. (1998). “Identification of the Low Density Lipoprotein Receptor-Binding Site in Apolipoprotein B100 and the Modulation of its Binding Activity by the Carboxyl Terminus in Familial Defective apo-B100,”J. Clin. Invest.101:1084-1093.
Camejo, G. et al. (1980). “Factors Modulating the Interaction of LDL with an Arterial Lipoprotein Complexing Proteoglycan: The Effect of HDL,”Acta. Med. Scand. Suppl.642:159-164.
Camejo, G. et al. (1988). “Identification of Apo B-100 Segments Mediating the Interaction of Low Density Lipoproteins with Arterial Proteoglycans,”Arteriosclerosis8:368-377.
Camejo, G. et al. (1993). “Binding of Low Density Lipoproteins by Proteoglycans Synthesized by Proliferating and Quiescent Human Arterial Smooth Muscle Cells,”J. Biol. Chem.268:14131-14137.
Capecchi, M. (1989). “Altering the Genome by Homologous Recombination,”Science244:1288-1292.
Cardin, A. et al. (1987). “Physical-Chemical Interaction of Heparin and Human Plasma Low-Density Lipoproteins,”Biochemistry26:5513-5518.
Cardoso, L.E. et al. (1994). “Glycosaminoglycan Fractions from Human Arteries Presenting Diverse Susceptibilities to Atherosclerosis Have Different Binding Affinities to Plasma LDL,”Arterioscler. Thromb.14:115-124.
Chang, Y. et al. (1983). “Proteoglycans Synthesized by Smooth Muscle Cells Derived from Monkey (Macaca nemestrina) Aorta,”J. Biol. Chem.258:5679-5688.
Christner, J.E. et al. (1990). “A Competitive Assay of Lipoprotein:Proteoglycan Interaction Using a 96-Well Microtitration Plate,”Analytical Biochem.184:388-394.
Corsini, A. et al. (1987). “Receptor Binding Activity of Lipid Recombinants of Apolipoprotein B-100 Thrombolytic Fragments”J. Lipid Res.28:1410-1423.
Costa, G. et al. (1994). “Polishing with T4 or Pfu Polymerase Increases the Efficiency of Cloning of PCR Fragments,”Nucleic Acids Res.22:2423.
Deng, W. et al. (1992). “Site-Directed Mutagenesis of Virtually Any Plasmid by Eliminating a Unique Site,”Anal. Biochem.200:81-88.
Edwards, I. et al. (1993). “Lipoprotein Lipase Enhances the Interaction of Low Density Lipoproteins with Artery-Derived Extracellular Matrix Proteoglycans,”J. Lipid Res.34:1155-1163.
Eisenberg, S. et al. (1992). “Lipoprotein Lipase Enhances Binding of Lipoproteins to Heparan Sulfate on Cell Surfaces and Extracellular Matrix,”J. Clin. Invest.90:2013-2021.
Gaffney, D. et al. (1995). “Independent Mutations at Codon 3500 of the Apoliprotein B Gene Are Associated with Hyperlipidemia,”Arterioscler. Thromb. Vasc. Biol.15:1025-1029.
Galis, Z. et al. (1993). “Co-Localization of Aortic Apolipoprotein B and Chondroitin Sulfate in an Injury Model of Atherosclerosis,”Am J. Pathol.142:1432-1438.
Geysen, H.M. et al. (1984). “Use of Peptide Synthesis to Probe Viral Antigens for Epitopes to a Resolution of a Single Amino Acid,”Proc. Natl. Acad. Sci. USA81:3998-4002.
Goldstein, J. et al. (1985). “Receptor-Mediated Endocytosis: Concepts Emerging from the LDL Receptor System,”Annu. Rev. Cell Biol.1:1-39.
Hirose, N. et al. (1987). “Isolation and Characterization of Four Heparin-Binding Cyanogen Bromide Peptides of Human Plasma Apolipoprotein B,”Biochemistry26:5505-5512.
Hobbs, H. et al. (1992). “Molecular Genetics of the LDL Receptor Gene in Familial Hypercholesterolemia,”Hum. Mutat.1:445-466.
Hoff, H et al. (1986). “Plasma Low Density Lipoprotein Accumulation in Aortas of Hypercholesterolemic Swine Correlates with Modifications in Aortic Glycosaminoglycan Composition,”Atherosclerosis.61:231-236.
Hoff, H. et al. (1983). “Apolipoprotein B Localization in Coronary Atherosclerotic Plaques from Cynomolgus Monkeys,”Artery12:104-116.
Hu, G. (1993). “DNA Polymerase-Catalyzed Addition of Nontemplated Extra Nucleotides to the 3'End of a DNA Fragment,”DNA and Cell Biology12:763-770.
Hurt, E. et al. (1987). “Effect of Arterial Proteoglycans on the Interaction of LDL with Human Monocyte-Derived Macrophages,”Atherosclerosis67:115-126.
Hurt, E. et al. (1990). “Interaction of LDL with Human Arterial Proteoglycans Stimulates its Uptake by Human Monocyte-Derived Macrophages,”J. Lipid Res.31:443-454.
Hurt-Camejo, E. et al. (1997). “Cellular Concequences of the Association of apoB Lipoproteins with Proteoglycans,”Arterioscler Thromb Vasc Biol.17:1011-1017.
Innerarity, T. et al. (1987). “Familial Defective Apolipoprotein B-100: Low Density Lipoproteins with Abnormal Receptor Binding,”Proc. Natl. Acad. Sci. USA84:6919-6923.
Innerarity, T. et al. (1990). “Familial Defective Apolipoprotein B-100: A Mutation of Apolipoprotein B that Causes Hypercholestrolemia,”J. Lipid Res.31:1337-1349.
Ismail, N. et al. (1994). “Lipoprotein-Proteoglycan Complexes from Injured Rabbit Aortas Accelerate Lipoprotein Uptake by Arterial Smooth Muscle Cells,”Atherosclerosis105:79-87.
Johnstone, A. et al. (1996). “Purification of Immunoglobulins,”Immunochemistry in Practice.Blackwell Scientific Publications; Oxford. p. 69.
Knott, T. et al (1985). “Human Apolipoprotein B: Stucture of Carboxyl-Terminal Domains, Sites of Gene Expression, and Chromosomal Localization,”Science.230:37-43.
Knott, T. et al. (1986). “Complete Protein Sequence and Identification of Structural Domains of Human Apolipoprotein B,”Nature323:734-738.
Kunkel, Thomas A. (1985). “Rapid and Efficient Site-Specific Mutagenesis Without Phenotypic Selection,”Proc. Natl. Acad. Sci. U.S.A.82:488-492.
Lindén, T. et al. (1989). “Affinity of LDL to a Human Arterial Proteoglycan Among Mal
Boren Jan
Innerarity Thomas
Gupta Anish
Morrison & Foerster / LLP
The Regents of the University of California
LandOfFree
Methods and tools for identifying compounds which modulate... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and tools for identifying compounds which modulate..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and tools for identifying compounds which modulate... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3441761